Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells

Endocrinology

Volumn 153, Issue 1, 2012, Pages 29-41

  Nithipatikom, Kasem ^a   Gomez Granados, Ana Doris ^a   Tang, Alan T ^a   Pfeiffer, Adam W ^a   Williams, Carol L ^a   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ACTIN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; ESTERASE INHIBITOR; MYOSIN; PROTEIN CDC42; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ACTIN FILAMENT; ARTICLE; CARCINOMA CELL; CELL MOTILITY; CELL SPREADING; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGULATORY MECHANISM;

ACTINS; ARACHIDONIC ACIDS; BENZOXAZINES; BIOLOGICAL TRANSPORT, ACTIVE; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; GLYCERIDES; HUMANS; MALE; MORPHOLINES; MYOSINS; NAPHTHALENES; PIPERIDINES; PROSTATIC NEOPLASMS; PYRAZOLES; RAC1 GTP-BINDING PROTEIN; RECEPTOR, CANNABINOID, CB1; RHOA GTP-BINDING PROTEIN;

EID: 84455160818     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1144     Document Type: Article

References (50)

1. Freimuth N, Ramer R, Hinz B 2010 Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 332:336-344
2. Bifulco M, Laezza C, Gazzerro P, Pentimalli F 2007 Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review). Oncol Rep 17:813-816
3. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M 2003 Inhibitory effects of cannabinoidCB1receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17:1771-1773
4. Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, Caruso MG, Notarnicola M, Iacuzzo I, Portella G, Di Marzo V, Bifulco M 2006 Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312:363-373 (Pubitemid 41804104)
5. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN 2008 Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68:6468-6476
6. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H 2008 Cannabinoids for cancer treatment: progress and promise. Cancer Res 68:339-342 (Pubitemid 351380057)
7. Maccarrone M 2008 Good news for CB1 receptors: endogenous agonists are in the right place. Br J Pharmacol 153:179-181
8. Petrosino S, Di Marzo V 2010 FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11:51-62
9. Nithipatikom K, Endsley MP, Isbell MA, Falck JR, Iwamoto Y, Hillard CJ, Campbell WB 2004 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64:8826-8830 (Pubitemid 39665485)
10. Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB 2005 A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332:1028-1033 (Pubitemid 40798189)
11. Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, Campbell WB, Nithipatikom K 2007 Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer 121:984-991 (Pubitemid 47101633)
12. Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K 2008 Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 123: 1318-1326
13. Raftopoulou M, Hall A 2004 Cell migration: Rho GTPases lead the way. Dev Biol 265:23-32 (Pubitemid 38018819)
14. Pollard TD, Borisy GG 2003 Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453-465 (Pubitemid 36263079)
15. Lambrechts A, Van Troys M, Ampe C 2004 The actin cytoskeleton in normal and pathological cell motility. Int J Biochem Cell Biol 36:1890-1909 (Pubitemid 38760020)
16. Wittchen ES, van Buul JD, Burridge K, Worthylake RA 2005 Trading spaces: Rap, Rac, and Rho as architects of transendothelial migration. Curr Opin Hematol 12:14-21 (Pubitemid 40189234)
17. Rao J, Li N 2004 Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 4:345-354 (Pubitemid 38797246)
18. Laezza C, Pisanti S, Malfitano AM, Bifulco M 2008 The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer 15:965-974
19. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF 2003 Requirement of RhoA activity for increased nuclear factor κB activity and PC-3 human prostate cancer cell invasion. Cancer Res 63:1359-1364 (Pubitemid 36348717)
20. Hwang YS, Hodge JC, Sivapurapu N, Lindholm PF 2006 Lysophosphatidic acid stimulates PC-3 prostate cancer cell matrigel invasion through activation of RhoA and NF-≲καππα∀B activity. Mol Carcinog 45: 518-529
21. Zhou C, Ling MT, Kin-Wah Lee T, Man K, Wang X, Wong YC 2006 FTY720, a fungus metabolite, inhibits invasion ability of androgen- independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett 233:36-47 (Pubitemid 43214562)
22. Edlund S, Landström M, Heldin CH, Aspenström P 2002 Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13:902-914 (Pubitemid 34250354)
23. Greenberg DL, Mize GJ, Takayama TK 2003 Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. Biochemistry 42:702-709 (Pubitemid 36133294)
24. Zheng R, Iwase A, Shen R, Goodman Jr OB, Sugimoto N, Takuwa Y, Lerner DJ, Nanus DM 2006 Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene 25:5942-5952 (Pubitemid 44477288)
25. Kelly P, Stemmle LN, Madden JF, Fields TA, Daaka Y, Casey PJ 2006 A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 281:26483-26490 (Pubitemid 44401857)
26. Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ 2007 PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. J Cell Biochem 101:1292-1300 (Pubitemid 47253727)
27. Nie D, Guo Y, Yang D, Tang Y, Chen Y, Wang MT, Zacharek A, Qiao Y, Che M, Honn KV 2008 Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res 68:115-121 (Pubitemid 351380112)
28. Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM 2005 Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 23:1037-1045 (Pubitemid 40637923)
29. Guilluy C, Rolli-Derkinderen M, Loufrani L, Bourg é A, Henrion D, Sabourin L, Loirand G, Pacaud P 2008 Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II type 2 receptor activation. Circ Res 102:1265-1274
30. Andresen BT, Shome K, Jackson EK, Romero GG 2005 AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity. Am J Physiol Renal Physiol 288:F763-F770 (Pubitemid 40381744)
31. Bishop AL, Hall A 2000 Rho GTPases and their effector proteins. Biochem J 348(Pt 2):241-255 (Pubitemid 30345195)
32. Epstein WW, Lever D, Leining LM, Bruenger E, Rilling HC 1991 Quantitation of prenylcysteines by a selective cleavage reaction. Proc Natl Acad Sci USA 88:9668-9670 (Pubitemid 21915692)
33. Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM,Lajoie-Mazenc I, Pradines A 2000 RhoAprenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 275:31001-31008
34. Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R, Williams CL 2008 SmgGDS regulates cell proliferation, migration, and NF- ≲καππα∀B transcriptional activity in non-small cell lung carcinoma. J Biol Chem 283:963-976
35. Strassheim D, May LG, Varker KA, Puhl HL, Phelps SH, Porter RA, Aronstam RS, Noti JD, Williams CL 1999 M3 muscarinic acetylcholine receptors regulate cytoplasmic myosin by a process involving RhoA and requiring conventional protein kinase C isoforms. J Biol Chem 274:18675-18685
36. Wang J, Zhao LY, Uyama T, Tsuboi K, Wu XX, Kakehi Y, Ueda N 2008 Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells. J Biochem 144:685-690
37. Klein TW, Lane B, Newton CA, Friedman H2000 The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225:1-8
38. Hurst D, Umejiego U, Lynch D, Seltzman H, Hyatt S, Roche M, McAllister S, Fleischer D, Kapur A, Abood M, Shi S, Jones J, Lewis D, Reggio P 2006 Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/ lysine3.28(192) interaction. J Med Chem 49:5969-5987 (Pubitemid 44484943)
39. Kapur A, Samaniego P, Thakur GA, Makriyannis A, Abood ME 2008 Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther 325:341-348 (Pubitemid 351439160)
40. Salo OM, Lahtela-Kakkonen M, Gynther J, Järvinen T, Poso A 2004 Development of a 3D model for the human cannabinoid CB1 receptor. J Med Chem 47:3048-3057 (Pubitemid 38702701)
41. Ahn KH, Nishiyama A, Mierke DF, Kendall DA 010 Hydrophobic residues in helix 8 of cannabinoid receptor 1 are critical for structural and functional properties. Biochemistry 49:502-511
42. Leeuwen FN, Kain HE, Kammen RA, Michiels F, Kranenburg OW, Collard JG 1997 The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho. J Cell Biol 139:797-807 (Pubitemid 27485843)
43. Williams MJ, Habayeb MS, Hultmark D 2007 Reciprocal regulation of Rac1 and Rho1 in Drosophila circulating immune surveillance cells. J Cell Sci 120:502-511 (Pubitemid 46332513)
44. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG 1999 Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 147:1009-1022
45. El-Sibai M, Pertz O, Pang H, Yip SC, Lorenz M, Symons M, Condeelis JS, Hahn KM, Backer JM 2008 RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent protrusion in MTLn3 carcinoma cells. Exp Cell Res 314:1540-1552
46. DerMardirossian C, Bokoch GM 2005 GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 15:356-363 (Pubitemid 40943524)
47. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J 1996 Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J 15:510-519 (Pubitemid 26044564)
48. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G 2000 Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoAinduced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 275:21722-21729
49. Forget MA, Desrosiers RR, Gingras D, Béliveau R 2002 Phosphorylation states of Cdc42 and RhoA regulate their interactions with RhoGDPdissociation inhibitor and their extraction from biological membranes. Biochem J 361:243-254 (Pubitemid 34174491)
50. Sawada N, Itoh H, Miyashita K, Tsujimoto H, Sone M, Yamahara K, Arany ZP, Hofmann F, Nakao K 2009 Cyclic GMP kinase and RhoA Ser188 phosphorylation integrate pro- and antifibrotic signals in blood vessels. Mol Cell Biol 29:6018-6032